• Mutation; HGNC; HGNC:8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-).
  
• Mutation; HGNC; HGNC:9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-).
  
• Mutation; HGNC; HGNC:9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-).
  
• Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Ser302fs*4 (c.906delC); Zygosity=Heterozygous (PubMed=20944090).
  
• Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-).
  
• Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (PubMed=20944090).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (PubMed=15901131).
  

PubMed=4031568
Nishida M., Kasahara K., Kaneko M., Iwasaki H., Hayashi K.
Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors.
Nihon Sanka Fujinka Gakkai Zasshi 37:1103-1111(1985)

PubMed=10381137; DOI=10.1016/S0304-3835(98)00270-5
Ohta H., Sakamoto H., Satoh K.
In vitro effects of gonadotropin-releasing hormone (GnRH) analogue on cancer cell sensitivity to cis-platinum.
Cancer Lett. 134:111-118(1998)

PubMed=12703541; DOI=10.1111/j.1749-0774.2002.tb00105.x
Nishida M.
The Ishikawa cells from birth to the present.
Hum. Cell 15:104-117(2002)

DOI=10.1007/978-4-431-53981-0_2
Nishida M.
Ishikawa cells: opening of in vitro hormone research on endometrial carcinoma.
(In book chapter) Cell and molecular biology of endometrial carcinoma; Kuramoto H., Nishida M. (eds.); pp.35-58; Springer; Tokyo; Japan (2003)

PubMed=15053063
Kamata Y., Watanabe J., Hata H., Hamano M., Kuramoto H.
Quantitative study on the correlation between p53 gene mutation and its expression in endometrial carcinoma cell lines.
Eur. J. Gynaecol. Oncol. 25:55-60(2004)

PubMed=15901131; DOI=10.1016/j.prp.2005.01.002
Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.
Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines.
Pathol. Res. Pract. 201:109-115(2005)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20218740; DOI=10.1177/153303461000900207; PMCID=PMC5120669
Wang Y.-M., Yang D., Cogdell D., Hu L.-M., Xue F.-X., Broaddus R., Zhang W.
Genomic characterization of gene copy-number aberrations in endometrial carcinoma cell lines derived from endometrioid-type endometrial adenocarcinoma.
Technol. Cancer Res. Treat. 9:179-189(2010)

PubMed=20944090; DOI=10.1126/scitranslmed.3001538
Dedes K.J., Wetterskog D., Mendes-Pereira A.M., Natrajan R., Lambros M.B., Geyer F.C., Vatcheva R., Savage K., Mackay A., Lord C.J., Ashworth A., Reis-Filho J.S.
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.
Sci. Transl. Med. 2:53ra75.1-53ra75.8(2010)

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017; PMCID=PMC3432677
Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Gynecol. Oncol. 127:241-248(2012)

PubMed=23255909; DOI=10.3892/ol.2012.975; PMCID=PMC3525505
Zhao S.-J., Li G.-X., Yang L., Li L., Li H.-Y.
Response-specific progestin resistance in a newly characterized Ishikawa human endometrial cancer subcell line resulting from long-term exposure to medroxyprogesterone acetate.
Oncol. Lett. 5:139-144(2013)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=36396974; DOI=10.1038/s41598-022-24211-8; PMCID=PMC9672046
Rush C.M., Blanchard Z., Polaski J.T., Osborne K.S., Osby K., Vahrenkamp J.M., Yang C.-H., Lum D.H., Hagan C.R., Leslie K.K., Pufall M.A., Thiel K.W., Gertz J.
Characterization of HCI-EC-23 a novel estrogen- and progesterone-responsive endometrial cancer cell line.
Sci. Rep. 12:19731-19731(2022)